SLS SELLAS Life Sciences Group Inc
Price (delayed)
$1.25
Market cap
$80.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.92
Enterprise value
$71.86M
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from
Highlights
SLS's EPS is up by 41% year-on-year and by 16% since the previous quarter
SELLAS Life Sciences Group's debt has decreased by 14% QoQ and by 8% YoY
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY
The quick ratio has contracted by 40% from the previous quarter and by 26% YoY
Key stats
What are the main financial stats of SLS
Market
Valuations
Earnings
Shares outstanding
64.33M
Market cap
$80.42M
Enterprise value
$71.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
24.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$34.44M
EBITDA
-$33.91M
Free cash flow
-$32.16M
Per share
Balance sheet
Liquidity
EPS
-$0.92
Free cash flow per share
-$0.56
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.23
Total assets
$15.12M
Total liabilities
$12.21M
Debt
$692,000
Equity
$2.91M
Working capital
$257,000
Debt to equity
0.24
Current ratio
1.02
Quick ratio
0.77
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-255.8%
Return on equity
-17,349.6%
Return on invested capital
N/A
Return on capital employed
-1,120.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLS stock price
How has the SELLAS Life Sciences Group stock price performed over time
Intraday
-0.79%
1 week
-5.3%
1 month
-5.3%
1 year
-16.67%
YTD
17.92%
QTD
5.04%
Financial performance
How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$34.8M
Net income
-$34.44M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 6% YoY and by 3.9% from the previous quarter
SELLAS Life Sciences Group's net income has increased by 4.5% YoY and by 3.8% QoQ
Growth
What is SELLAS Life Sciences Group's growth rate over time
Valuation
What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
24.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS is up by 41% year-on-year and by 16% since the previous quarter
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY
Efficiency
How efficient is SELLAS Life Sciences Group business performance
SELLAS Life Sciences Group's return on assets has shrunk by 68% YoY and by 2.3% QoQ
Dividends
What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLS.
Financial health
How did SELLAS Life Sciences Group financials performed over time
The total assets is 24% greater than the total liabilities
The quick ratio has contracted by 40% from the previous quarter and by 26% YoY
The total assets has declined by 38% since the previous quarter and by 19% year-on-year
SELLAS Life Sciences Group's debt is 76% lower than its equity
The debt to equity has soared by 200% from the previous quarter and by 60% YoY
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.